Intermediate- and high-risk prostate cancer: A plea for high-dose, high-precision intensity-modulated radiotherapy with a modulated duration of androgen deprivation therapy

European Urology

Volumn 60, Issue 6, 2011, Pages 1140-1141

  Bolla, Michel ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; LUTEOTROPHIN RELEASING HORMONE AGONIST; PROLACTIN RELEASING FACTOR; UNCLASSIFIED DRUG;

ACCURACY; ANDROGEN DEPRIVATION THERAPY; CANCER RISK; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 80255123794     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.09.006     Document Type: Editorial

References (10)

1. M.J. Zelefsky, X. Pei, and J.F. Chou Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes Eur Urol 60 2011 1133 1139
2. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of later rectal and urinary toxicities after three dimensional conformal radiotherapy and intensity modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 2008 1124 1129 (Pubitemid 351296130)
3. P.A. Kupelian, J. Ciezki, and A.R. Chandana Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer Int J Radiat Oncol Biol Phys 71 2008 16 22 (Pubitemid 351491401)
4. D. Krauss, L. Kestin, and H. Ye Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate and high risk prostate cancer Int J Radiat Oncol Biol Phys 80 2011 1064 1071
5. B.M. Dubray, V. Beckendorf, and S. Guerif Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediate analysis of GETUG 14 randomized trial (EU-20503/NCT00104741) J Clin Oncol 29 Suppl 2011 abstract 4521
6. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295 (Pubitemid 351159365)
7. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
8. A. Zapatero, F. Valcarcel, and F.A. Calvo Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study J Clin Oncol 23 2005 6561 6568 (Pubitemid 46190249)
9. M. Bolla, G. van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study Lancet Oncol 11 2010 1066 1073
10. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527